Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02114


Purpose:

Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.


Study summary:

This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine bolus/infusions in acutely burned pediatric patients. The study entails a bolus of dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters including EKG, heart rate, oxygen saturation, blood pressure, are recorded.


Criteria:

Inclusion Criteria: - pediatric patient - >25% total body surface area (tbsa) burn and < 90% tbsa - opioid requirements > 0.1 mg/kg/hour of morphine (or equivalent) - midazolam requirement > 0.1 mg/kg/hour - treatment team determined that patient should be started on dexmedetomidine Exclusion Criteria: - hemodynamically unstable patients (epinephrine > 1.0 ug/kg/min, levophed > 0.75 ug/kg/min, dopamine > 10 ug/kg/min) - pregnant patients - patients with history of heart block - patients with congenital heart disease - patients with significant hepatic dysfunction - patients with urine output < 0.5 ml/kg/hour [averaged] over past 24 hours


NCT ID:

NCT00697788


Primary Contact:

Principal Investigator
Erik S Shank, MD
Massachusetts General Hospital


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02114
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.